NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Umibe5690,

This article validates many findings from the Phase 1 DCVax-L trial and updates them with more specifics based on a newer understanding of IDHmt vs IDHwt. DC vaccines and mesenchymal subtype have long been linked to benefit with M+ mesenchymal showing best results. The IDH classification further stratifies the mesenchymal subtype and others. This subtype provides more neoantigens, some of which are easily accessed by circulating DCs and previously activated T-cells during the process of recurrence. This often includes transition to mesenchymal subtype and a mesenchymal motility marker found In exozomes which are shed from remaining tumor cell source(s). This explains why the comment about checkpoint inhibitors being more effective in certain subtypes was made albeit without mention of the need for them in some cases perhaps because DCVax-L might be enough on its own. Best wishes.